However, the European Medicines Agency (EMA) rejected a request of Vivus, the manufacturer of Qsymia, for authorization to supply these diet pills to the European market because of cardiovascular risks.
Before using Qsymia, it is recommended to evaluate appropriateness of obesity pharmacotherapy, or to establish an adequate dosage schedule.
When using Qsymia, risk of arrhythmia or elevated blood pressure increases in patients with cardiovascular diseases. Therefore, obese patients with cardiac dysfunctions are advised to take precautions during obesity pharmacotherapy.
Qsymia has a potential teratogenic risk. During a course of these diet pills, women should use barrier methods of birth control and / or oral contraceptives. If a woman becomes pregnant during Qsymia course, obesity pharmacotherapy should be stopped.
Qsymia also has a potential risk of psychiatric disorders, such as suicidal thoughts or depression. These Qsymia undesirable events quickly pass after completion of obesity pharmacotherapy course.
To reduce a potential risk of hypoglycemia, obese diabetics may need a reduction of Metformin or Insulin dose during Qsymia course.
Phentermine, one of the Qsymia components, has a dependence potential. However, this drug for obesity treatment includes minimal doses of active ingredients. Therefore, Qsymia has a minimal risk of dependence.